KEDI Global Obesity Care Industry Top 2+ Index

Novo Nordisk is scheduled to release its Q1 2026 earnings report before the market opens on May 6, 2026, with high importance estimated due to potential 10% price impact, expected.

Life Time Group Holdings is scheduled to report its Q1 2026 financial results. A moderate market reaction is estimated for this standard earnings release scheduled.

Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, followed by a conference call. High impact is estimated due to significant market focus on GLP-1 sales growth scheduled.

Merck & Co. is scheduled to release its Q1 2026 earnings on April 30, 2026; impact is estimated as neutral pending the actual report, scheduled.

Amgen is expected to report its Q1 2026 financial results after the market closes on April 30, 2026, scheduled. Analysts estimate a Low impact (~1-2%) as a standard scheduled reporting event, scheduled.

AstraZeneca's Q1 2026 results announcement is scheduled for April 29, 2026 scheduled

Novartis is scheduled to report Q1 2026 results on 2026-04-28; analysts forecast EPS of about USD 2.10, making this a near-term earnings catalyst with estimated low neutral impact until results are released. scheduled

Abbott announced Q1 2026 results, beating revenue estimates but lowering its full-year 2026 adjusted EPS forecast to $5.38-$5.58, citing $0.20 of dilution from the Exact Sciences acquisition.

Eli Lilly is expected to announce Foundayo's heart safety trial results and the FDA's request for additional data on April 16, 2026. Medium impact is estimated based on the clinical significance of obesity treatments expected.

Scheduled for April 16, 2026, BTIG initiated coverage with a 'Buy' rating and a $300 price target, citing potential upside from the Foot Locker acquisition; low importance as analyst initiations typically have limited price impact, estimated.

Novo Nordisk and OpenAI announced a strategic partnership on April 14, 2026, to integrate advanced AI for discovering and delivering new medicines.

The FDA approved the first generic versions of AstraZeneca's blockbuster Type 2 diabetes drug, Farxiga, on April 13, 2026. This will introduce significant competition and likely lead to sales erosion.

The U.S. FDA granted Priority Review for the Biologics License Application for ifinatamab deruxtecan for a type of small cell lung cancer on April 13, 2026. The PDUFA action date is set for October 10, 2026.